← FDA DRUG APPROVALS

FDA NDA · NDA011738

NUMORPHAN

Sponsor: ENDO PHARMS

APPLICATION
NDA011738
TYPE
NDA
ORIGINAL APPROVAL
1960-05-31
LATEST ACTION
2000-09-25
ROUTE
RECTAL
DOSAGE FORM
SUPPOSITORY
MARKETING STATUS
Discontinued

Products

NUMORPHANDiscontinued
OXYMORPHONE HYDROCHLORIDE 5MG · SUPPOSITORY · RECTAL

Approval history

2000-09-25Manufacturing (CMC) · Supplement 12 · standardAP
1997-10-29Labeling · Supplement 13 · standardAP
1996-10-15Labeling · Supplement 11 · standardAP
1994-05-11Manufacturing (CMC) · Supplement 10 · standardAP
1981-11-04Manufacturing (CMC) · Supplement 7 · standardAP
1960-05-31Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →